Hunan Jiudian Pharmaceutical (300705)2024-12-25 10:05Group 1: Company Overview - The company is Hunan Jiudian Pharmaceutical Co., Ltd., with stock code 300705 and bond code 123223 [1] Group 2: Investor Relations Activity - The investor relations activity took place on December 25, 2024, from 1:00 PM to 2:30 PM in the company meeting room [2] - Representatives from Huayuan Securities and ICBC Credit Suisse participated, totaling 4 individuals [2] Group 3: Product Sales and Market Strategy - The sales strategy for various products includes both hospital and outpatient channels, with a focus on increasing sales volume for the Loxoprofen Sodium Gel Patch [2] - The Ketoprofen Gel Patch is included in the national medical insurance drug list, primarily focusing on hospital sales, while online sales are minimal [2] - The newly launched anti-inflammatory pain relief patch primarily utilizes OTC channels for sales [3] Group 4: Research and Development - The company is developing a traditional Chinese medicine product, the Jiao Qi She Gel Patch, expected to complete clinical research in 1-2 years for re-application [2] - Current R&D focuses on generic drugs, with an emphasis on high-end formulations and innovative transdermal delivery systems [2] - Future plans include a shift towards innovative drugs, supported by a foundation of generic drugs [2] Group 5: Product Differentiation - Key differences between gel patches and adhesive patches include formulation type, matrix materials, and preparation processes [3] - Gel patches are expected to be more comfortable and skin-friendly, while adhesive patches offer better adhesion for active areas [3] - Anticipated approvals for external preparations include Indomethacin Gel Patch and Flurbiprofen Gel Patch by 2025, and Loxoprofen Sodium Patch and Ketoprofen Patch by 2026 [3] Group 6: Market Expansion and Future Plans - The company plans to expand its outpatient market by collaborating with chain pharmacies, targeting provinces such as Yunnan, Guangdong, Hunan, Sichuan, Hebei, and Gansu for OTC sales of Loxoprofen Sodium Gel Patch [5] - Potential products for future centralized procurement include Dimethicone Emulsion, Indobufen Tablets, Lansoprazole Enteric-Coated Capsules, Dapagliflozin Tablets, Ferrous Succinate Tablets, and Nicorandil Tablets [3] Group 7: Employee Incentives - The company plans to introduce an employee stock incentive plan to enhance governance and align interests between the company and core employees, thereby boosting employee motivation [4]